Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 189

The DOI matches its Crossref record.

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

Open access
Karapanagiotou, Eleni M., Roulstone, Victoria, Twigger, Katie, Ball, Mercel, Tanay, MaryAnne, Nutting, Chris, Newbold, Kate, Gore, Martin E., Larkin, James, Syrigos, Konstantinos N., Coffey, Matt, Thompson, Brad, Mettinger, Karl, Vile, Richard G., Pandha, Hardev S., Hall, Geoff D., Melcher, Alan A., Chester, John, Harrington, Kevin J. · 2012 · Clinical Cancer Research

Abstract

Purpose: Reovirus type 3 Dearing (RT3D) replicates preferentially in Ras-activated cancers. RT3D shows synergistic in vitro cytotoxicity in combination with platins and taxanes. The purpose of this phase I/II study was to assess RT3D combined with carboplatin/paclitaxel in patients with advanced cancers. Experimental Design: Patients were initially treated in a dose-escalating, phase I trial with intravenous RT3D days 1 to 5, carboplatin [area under curve (AUC) 5, day 1] and paclitaxel (175 mg/m2, day 1) 3-weekly. RT3D was escalated through three dose levels: 3 × 109, 1 × 1010, and 3 × 1010 TCID50 in cohorts of three. Primary endpoints were to define the maximum tolerated dose and dose-limiting toxicity and to recommend a dose for phase II studies. Secondary endpoints included pharmacokinetics, immune response, and antitumor activity. A subsequent phase II study using the 3 × 1010 TCID50 dose characterized the response rate in patients with head and neck cancer. Results: Thirty-one heavily pretreated patients received study therapy. There were no dose-limiting toxicities during dose-escalation and most toxicities were grade I/II. Overall effectiveness rates were as follows: one patient had a complete response (3.8%), six patients (23.1%) had partial response, two patients (7.6%) had major clinical responses clinically evaluated in radiation pretreated lesions which are not evaluable by Response Evaluation Criteria in Solid Tumors (RECIST), nine patients (34.6%) had stable disease, and eight patients (30.8%) had disease progression. Viral shedding was minimal and antiviral immune responses were attenuated compared with previous single-agent data for RT3D. Conclusions: The combination of RT3D plus carboplatin/paclitaxel is well tolerated with evidence of activity in cancer of the head and neck. A randomized phase III study is currently open for recruitment. Clin Cancer Res; 18(7); 2080–9. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-11-2181

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 189

Metadata

Authors
Karapanagiotou, E. M., Roulstone, V., Twigger, K., Ball, M., Tanay, M., Nutting, C., Newbold, K., Gore, M. E., Larkin, J., Syrigos, K. N., Coffey, M., Thompson, B., Mettinger, K., Vile, R. G., Pandha, H. S., Hall, G. D., Melcher, A. A., Chester, J., & Harrington, K. J.
Venue
Clinical Cancer Research
Published
2012-04-01
Volume
18
Issue
7
Pages
2080-2089
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2147621051
Cited by
189
References
0
FWCI
13.46
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-2181
The paper
Karapanagiotou, E. M., Roulstone, V., Twigger, K., Ball, M., Tanay, M., Nutting, C., Newbold, K., Gore, M. E., Larkin, J., Syrigos, K. N., Coffey, M., Thompson, B., Mettinger, K., Vile, R. G., Pandha, H. S., Hall, G. D., Melcher, A. A., Chester, J., & Harrington, K. J. (2012). Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-2181

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.